Hot or Cold

RKLB stock sentiment todayRocket Lab Corp

Sentiment verdict

Gossip first, financials second — HOT at 85% confidence.

Last updated · cached analysis, refreshes periodically

NASDAQ

RKLB

Rocket Lab Corp
54.73 USD▼ 1.76%vs. session open
After hours · market closedQuote as of Nov 1, 10:25 AM UTC
HOT85% confidenceSign in to save

The only proven commercial alternative to SpaceX, transitioning from a small-sat launcher to a heavy-lift and space-systems powerhouse.

Analyzed Nov 1, 2026, 01:57 AM UTC·Quote: CNBC / Yahoo Finance·News: Google News·Targets: StockAnalysis.com·AI: Lovable AI (google/gemini-3-flash-preview)
Tone“RKLB is HOT — The only proven commercial alternative to SpaceX, transitioning from a small-sat launcher to a heavy-lift and space-systems powerhouse. 6-month call: USD66.95 (+22.3%).”
6-month price prediction
USD66.95▲ 22.3%by May 2027
45% model confidence
Bear USD26.78Now USD54.73Bull USD107.12
Crowd call · 6 months
No predictions yet

Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.

Make your call as a guest

You'll show up on boards and The Floor under this name. Add an email later to keep your history.

No account needed. You can add an email later to keep your calls.

Already have an account? Sign in

🔒 Full prediction model breakdown

See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.

Sign in to go Pro →

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for RKLB. Not financial advice.

02·a

Price · last 12 months

39.48 – 150.23 USD
Growth
1W
+4.0%
1M
-21.5%
3M
-22.3%
6M
-31.9%
YTD
-28.0%
1Y
-10.8%
01

Gossip

bullish

Market narrative is dominated by the 'Neutron' anticipation and the company's success in winning massive defense and commercial satellite bus contracts. Investors view RKLB as the clear #2 behind SpaceX, benefiting from a 'monopoly fatigue' in the launch industry.

  • ·Successful hot fire tests of the Archimedes engine
  • ·Increasing backlog of launch manifests for Electron
  • ·Expansion into space systems (components/satellites) providing higher margins than launch
  • ·Short-squeeze potential following recent volatility and high retail interest
02

Financial

strong

While not yet GAAP profitable, revenue growth is accelerating (70%+ YoY) and the balance sheet is fortified by over $500M in cash. Margin expansion is evident as the Space Systems segment now accounts for the majority of revenue.

  • ·Revenue Growth: 71% YoY in recent quarters
  • ·Backlog: Exceeding $1.0 billion
  • ·Cash Position: ~$500M to fund Neutron development
  • ·Gross Margins: Improving toward 30%+ as manufacturing scales
02b

Conviction

Mixed

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

61conviction score / 100

Mixed conviction — no decisive signal from insiders or the holder base.

  • ·Insiders sold a net $47K on the open market in the last 120 days.
Insider buys (120d)
0
Net insider flow
-$47K
Patient capital
66%
🔒 Who bought, and who's holding

Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.

Unlock with Pro →

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

03

Risks

watch
  • ·Execution risk regarding the 2025 Neutron maiden flight schedule
  • ·High capital expenditure requirements for launch infrastructure
  • ·Potential dilution if additional capital is raised for constellation deployment
05

Analyst price target

HOT
97.33 USD▲ 77.8% vs current

Consensus average of 18 analysts · median 105.00

Low 60.00High 132.00

Source: StockAnalysis.com · updated 2026-10-19

AI-generated analysis for informational purposes only. Not financial advice.